scout
|Videos|November 17, 2017

Dr. Lara on the FDA Approval of Adjuvant Sunitinib in RCC

Primo N. Lara Jr, MD, associate director for translational research, UC Davis Comprehensive Cancer Center, discusses the FDA approval of adjuvant sunitinib (Sutent) for high-risk patients with renal cell carcinoma (RCC).

Primo N. Lara Jr, MD, associate director for translational research, UC Davis Comprehensive Cancer Center, discusses the FDA approval of adjuvant sunitinib (Sutent) for high-risk patients with renal cell carcinoma (RCC).

Newsletter

Stay up to date on the most recent and practice-changing oncology data


Latest CME